Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed Categories

Benzinga Newsdesk www.benzinga.com Negative 73.2%

Neg 73.2% Neu 0% Pos 0%

Comments

No comments yet. Be the first!